Technology | Radiation Therapy | October 20, 2017

System provides high-dose treatment for various types of skin cancer

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance

October 20, 2017 — Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k) clearance for treatment of skin cancer. The Photoelectric Therapy System is a compact and ergonomic superficial X-ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

Utilizing trusted and clinically proven low energy photons in a dedicated treatment system, the Photoelectric Therapy System provides a pain-free, non-surgical alternative for the treatment of non-melanoma skin cancer and superficial lesions, especially those found in sensitive areas of the head and neck.

Using an ideal depth dose profile for the treatment of superficial skin lesions, the high dose output enables treatment times to be kept to a minimum in the same manner as electronic brachytherapy systems while treating a wider range of skin conditions. The low half-value layer (HVL) of the system allows for higher doses without compromising on depth of delivery.

Typical applications include treatment for:

  • Basal cell carcinoma;
  • Squamous cell carcinoma;
  • Metatypic carcinoma;
  • Cutaneous appendage carcinoma;
  • Karposi's sarcoma;
  • Merkel cell carcinoma;
  • Lentigo maligna;
  • Lentigo maligna melanoma;
  • Cutaneous lymphomas (B and T cell); and
  • Keloids.

The system is freestanding, self-contained, unobtrusive, compact and lightweight, which helps to ensure a reassuring and stress-free patient experience in any clinical facility. The system is mounted on lockable castors, allowing free movement and operation in any clinical space. It features ergonomically designed controls ensuring smooth adjustment and safe, simple patient set-up. The system requires connection to the clinical facilities electrical supply and room interlocks, but generates X-rays using a 24V power supply.

Photoelectric therapy devices require minimal shielding as compared to higher energy X-ray therapy systems.

For more information: www.xstrahl.com


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
Subscribe Now